During the first half of study Phase II, trial SCS will be delivered to the subdural lead only (i.e. the epidural lead will be off). Methodological limitations prevent randomization of the order in which trial leads are activated in Phase II, so study staff will not be blinded to the location of the active SCS lead. However, subjects will not be told which trial lead is in use until the study is complete. The SJM representative will initially program the subdural trial lead on the day of surgery with standard stimulation settings. Subjects will assess their current pain intensity using a numeric rating scale (NRS) taken from the short-form BPI, item #6. Subjects will then be discharged from the hospital after receiving pain questionnaires and diaries to fill out over the next three days. On each of following two days, subjects will complete pain and quality of life ratings using the short from BPI, EQ-5D-5L descriptive system, and two NRS pain assessments; paresthesia coverage map and paresthesia quality ratings will also be completed to quantify sensory responses to SCS. On the third day following surgery, subjects will not complete NRS pain assessments, but will instead complete the SF-MPQ-2 and SAT in addition to the other ratings. This will conclude the first half of study Phase II.